Brett J Loechelt, Michael Green, Peter A Gottlieb, Emily Blumberg, Adriana Weinberg, Scott Quinlan, Lindsey R Baden
Significant progress has been made in the development, investigation, and clinical application of immunosuppressive agents to treat a variety of autoimmune disorders. The expansion of clinical applications of these new agents requires the performance of large multicenter clinical trials. These large clinical trials are particularly important as one considers these agents for the treatment of type 1 diabetes, which although autoimmune in its pathogenesis, is not classically treated as an autoimmune disorder...
September 2015: Journal of the Pediatric Infectious Diseases Society